QURE uniQure N.V.

49.73
+1.65  (+3%)
Previous Close 48.08
Open 48.55
52 Week Low 34.38
52 Week High 76.6869
Market Cap $2,212,793,092
Shares 44,496,141
Float 44,278,298
Enterprise Value $1,894,328,662
Volume 459,925
Av. Daily Volume 405,875
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
AMT-061 (HOPE-B)
Hemophilia B
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
AMT-130
Huntington's disease
Phase 1/2
Phase 1/2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. LEXINGTON, Mass and AMSTERDAM, Dec. 02, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that its participation in the following upcoming virtual investor and scientific conferences:

    • Evercore ISI 3rd Annual HealthCONx Conference, December 1 - 3, 2020

    • A fireside chat with Ricardo Dolmetsch, Ph.D., president of research & development, will take place today, December 2, 2020 from 8:25 – 8:45 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.

    • Members…

    LEXINGTON, Mass and AMSTERDAM, Dec. 02, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that its participation in the following upcoming virtual investor and scientific conferences:

    • Evercore ISI 3rd Annual HealthCONx Conference, December 1 - 3, 2020

    • A fireside chat with Ricardo Dolmetsch, Ph.D., president of research & development, will take place today, December 2, 2020 from 8:25 – 8:45 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.



    • Members of uniQure's management team including Matt Kapusta, chief executive officer, Ricardo Dolmetsch, Ph.D., president of research & development, and Maria Cantor, chief communications officer, with Chiara Russo, associate director of investor relations and communications, also will participate in virtual one-on-one investor meetings throughout the day.

    • American Society of Hematology (ASH) Annual Meeting, December 5 - 8, 2020

    • Dr. Steven Pipe, M.D., professor of pediatrics and pathology and pediatric medical director of the hemophilia and coagulation disorders program at the University of Michigan, will present clinical data from the HOPE-B pivotal trail of etranacogene dezaparvovec in hemophilia B as part of the ASH Late-Breaking Oral Presentations on Tuesday, December 8, 2020 at 11:45 a.m. ET.



    • Following the late-breaking oral presentation, uniQure management and Dr. Pipe will host an investor webcast at 5:00 p.m. ET to review the pivotal top-line HOPE-B data presented at ASH. The live webcast along with slides can be accessed through the link displayed in the Investor section of the uniQure website. The webcast will be archived for 90 days.

    • 2nd Annual Gene Therapy Conference for Neurological Disorders, December 8-10, 2020

    • Lisa Spronck, ERT, a scientist in non-clinical development, will present "First-in-Human AAV Gene Therapy for Huntington's Disease from Pre-Clinical to the Clinic" on Thursday, December 10 at 8:55 a.m. ET.

    • Lega Italiana Ricerca Huntington Annual Conference, December 12, 2020

    • David Cooper, M.D., vice president of clinical research CNS, will present "Updates on HD-GeneTRX-1: A Phase 1/2 Clinical Trial of CNS-administered Gene Therapy (AMT-130) for Early-Stage HD" on Saturday, December 12 at 11:40 a.m. CET.

    About uniQure

    uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

    uniQure Contacts:

    FOR INVESTORS:   FOR MEDIA:
         
    Maria E. Cantor Chiara Russo  Tom Malone
    Direct: 339-970-7536 Direct: 617-306-9137 Direct:  339-970-7558
        



    Primary Logo

    View Full Article Hide Full Article
  2. ~ Strong Presence at ASH Featuring Five Presentations, Including Late-Breaking
    Oral Presentation on HOPE-B Pivotal Trial ~

    ~ uniQure to Host Investor Webcast Tuesday, December 8, 2020 at 5:00 p.m. ET ~

    LEXINGTON, Mass. and AMSTERDAM, Nov. 30, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that Steven Pipe, M.D., professor of pediatrics and pathology and pediatric medical director of the hemophilia and coagulation disorders program at the University of Michigan, will present clinical data from the HOPE-B pivotal trial of etranacogene dezaparvovec in hemophilia B at the virtual 62nd American Society of Hematology (ASH…

    ~ Strong Presence at ASH Featuring Five Presentations, Including Late-Breaking

    Oral Presentation on HOPE-B Pivotal Trial ~

    ~ uniQure to Host Investor Webcast Tuesday, December 8, 2020 at 5:00 p.m. ET ~

    LEXINGTON, Mass. and AMSTERDAM, Nov. 30, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that Steven Pipe, M.D., professor of pediatrics and pathology and pediatric medical director of the hemophilia and coagulation disorders program at the University of Michigan, will present clinical data from the HOPE-B pivotal trial of etranacogene dezaparvovec in hemophilia B at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

    • Dr. Pipe, principal investigator of the HOPE-B pivotal trial, will participate in the ASH press briefing scheduled for Monday, December 7 from 10:30 a.m. – 11 a.m. E.T.
    • Dr. Pipe will present a late-breaking oral presentation on the HOPE-B data on Tuesday, December 8 at 11:45 a.m. E.T.

    uniQure management along with Dr. Pipe will host an investor webcast on Tuesday, December 8, 2020, at 5:00 p.m. ET. To access the live webcast with presentation slides, please visit the Investor Relations section of uniQure's website at www.uniQure.com. The webcast will be archived for 90 days. The event also may be accessed by dialing (877) 870 – 9135 for domestic callers and +44 020 719 283 38 for international callers. The passcode is 3164585. Please specify to the operator that you would like to join the "uniQure Conference Call."

    Late-Breaking Oral Presentation

      
    Title:First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies
    Presenter:Steven Pipe, M.D.
    Session Name:Late-Breaking Abstracts, LBA-6
    Date:Tuesday, December 8, 2020
    Presentation Time:11:45 a.m. ET (8:45 a.m. PT)
      
    Oral Presentation 
      
    Title:Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial
    Presenter:Annette von Drygalski, M.D., PharmD
    Session Name:801. Gene Editing, Therapy and Transfer I
    Date:Monday, December 7, 2020
    Presentation Time:2:45 p.m. ET (11:45 a.m. PT)
      
    Poster Presentations 
      
    Title:AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years
    Session Name:801. Gene Editing, Therapy and Transfer: Poster III
    Date:Monday, December 7, 2020
    Presentation Time:10:00 a.m. - 6:30 p.m. ET (7:00 a.m. - 3:30 p.m. PT)
      
    Title:A Single Administration of AAV5-hFIX in Newborn, Juvenile and Adult Mice Leads to Stable hFIX Expression up to 18 Months after Dosing 
    Session Name:801. Gene Editing, Therapy and Transfer: Poster II
    Date:Sunday, December 6, 2020
    Presentation Time:10:00 a.m. - 6:30 p.m. ET (7:00 a.m. - 3:30 p.m. PT)
      
    Title:Examining the Hemophilia Disability Paradox
    Session Name:904. Outcomes Research—Non-Malignant Conditions: Poster II
    Date:Sunday, December 6, 2020
    Presentation Time:10:00 a.m. - 6:30 p.m. ET (7:00 a.m. - 3:30 p.m. PT)

    The conference abstracts are available and can be accessed through this link: ASH abstracts.

    About uniQure

    uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

    uniQure Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, whether we will present long-term follow-up data from our hemophilia B gene therapy studies, including two years of follow-up on the Phase IIb clinical trial of etranacogene dezaparvovec (AMT-061) and up to five years of follow-up from the Phase I/II clinical trial of AMT-060, and whether we will announce top-line data from the pivotal HOPE-B study of etranacogene dezaparvovec before the end of this year. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our and our collaborators' clinical development activities, clinical results, collaboration arrangements, corporate reorganizations and strategic shifts, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's Quarterly Report on Form 10-Q filed on October 27, 2020. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

    uniQure Contacts:

    FOR INVESTORS: FOR MEDIA:
       
    Maria E. CantorChiara RussoTom Malone
    Direct: 339-970-7536Direct: 617-306-9137Direct: 339-970-7558
    Mobile: 617-680-9452Mobile: 617-306-9137Mobile:339-223-8541



    Primary Logo

    View Full Article Hide Full Article
  3. ~ Phase III study in 54 patients met primary endpoint with mean Factor IX activity of 37% of normal at 26 weeks ~

    ~ Patients achieved significant increases in Factor IX activity irrespective of pre-existing neutralizing antibodies, potentially supporting broad patient access ~

    ~ Increases in Factor IX activity were sustained for up to 18 months with near elimination of bleeding ~

    ~ Mean annualized usage of FIX replacement therapy declined by 96 percent after dosing compared to the observational lead-in period ~

    ~ Etranacogene dezaparvovec was well-tolerated with no treatment-related serious adverse events ~

    ~ Data selected for late-breaker oral presentation on December 8, 2020 at the Annual Meeting of the American Society of Hematology…

    ~ Phase III study in 54 patients met primary endpoint with mean Factor IX activity of 37% of normal at 26 weeks ~

    ~ Patients achieved significant increases in Factor IX activity irrespective of pre-existing neutralizing antibodies, potentially supporting broad patient access ~

    ~ Increases in Factor IX activity were sustained for up to 18 months with near elimination of bleeding ~

    ~ Mean annualized usage of FIX replacement therapy declined by 96 percent after dosing compared to the observational lead-in period ~

    ~ Etranacogene dezaparvovec was well-tolerated with no treatment-related serious adverse events ~

    ~ Data selected for late-breaker oral presentation on December 8, 2020 at the Annual Meeting of the American Society of Hematology (ASH) ~

    LEXINGTON, Mass. and AMSTERDAM, Nov. 19, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced positive top-line data from its pivotal, Phase III HOPE-B gene therapy trial of etranacogene dezaparvovec, an investigational adeno-associated virus five (AAV5)-based gene therapy for the treatment of patients with severe and moderately severe hemophilia B. This is the first data set to be reported from a Phase III gene therapy study in hemophilia B and, with 54 patients, the largest set of patients receiving a single gene therapy investigational product to be reported to date. These clinical data were published today as a late-breaking abstract, one of only six accepted for presentation at the 62nd Annual Meeting of the American Society of Hematology (ASH) and will be featured as an oral presentation in the conference on December 8, 2020. The abstract is available here.

    "We are extremely pleased that these top-line pivotal data show that a single administration of etranacogene dezaparvovec gene therapy led to sustained increases of Factor IX (FIX) to functionally-curative levels capable of eliminating the need for regular infusions to control and prevent bleeding episodes," stated Ricardo Dolmetsch, Ph.D., president of research and development at uniQure. "Most impressively, these data also demonstrate the potential to achieve clinical benefit in patients with a range of pre-existing neutralizing antibodies representative of the general population. The ability to dose a gene therapy in patients with pre-existing neutralizing antibodies has not been demonstrated for any other gene therapy and illustrates the potentially unique ability of our AAV5 platform to address the needs of a broad set of patients living with hemophilia B and other disorders."

    The pivotal, Phase III HOPE-B clinical trial of etranacogene dezaparvovec is an open-label, single-dose, single-arm, multi-national trial in adult males with severe or moderately severe hemophilia. All patients required prophylactic routine FIX replacement prior to entering the clinical trial, and patients were not excluded from the trial based on pre-existing neutralizing antibodies (NAbs) to AAV5.

    Patients in the HOPE-B clinical study were initially enrolled into a prospective, observational lead-in period of at least six months during which bleeding events and FIX replacement therapy usage were monitored. Fifty-four patients received a single intravenous infusion of etranacogene dezaparvovec gene therapy at 2x1013 gc/kg, including 23 patients who had pre-existing NAbs to AAV5. Patients are then evaluated to assess FIX activity determined by a one-stage assay performed at a central laboratory, annualized bleeding rates and usage of Factor IX replacement therapy. Patients will be monitored for five years to evaluate the safety of etranacogene dezaparvovec.

    HOPE-B Primary Endpoint of FIX Activity at 26 Weeks Achieved, Irrespective of Pre-Existing NAbs

    FIX activity in the 54 patients increased rapidly after dosing from ≤2% to a mean of 37.2 percent at 26 weeks, meeting the first primary endpoint. No correlation between pre-existing NAbs and FIX activity was found in patients with NAb titers up to 678.2, a range expected to include more than 95% of the general population; one patient with a NAb titer of 3,212.3 did not show an increase in FIX activity.   

    During the 26-week period after dosing, 72 percent of patients (39/54) reported no bleeding events. Fifteen patients reported a total of 21 bleeds1. Mean annualized usage of FIX replacement therapy, a secondary endpoint in the clinical trial, declined by 96 percent.

    Etranacogene dezaparvovec was generally well-tolerated with no treatment-related serious adverse events. Most adverse events were classified as mild (81.5 percent). Most common events included transaminase elevation treated with steroids per protocol (9 pts; 17%), infusion-related reactions (7 pts; 13%), headache (7 pts; 13%) and influenza-like symptoms (7 pts; 13%). Liver enzyme elevations resolved with a tapering course of corticosteroids and FIX activity remained in the mild range in the steroid treated patients. No relationship between safety and NAbs titers was observed.

    "We believe that etranacogene dezaparvovec has the potential to be a first- and best-in-class gene therapy for patients with hemophilia B," stated Matt Kapusta, chief executive officer of uniQure. "We are very pleased to have met the 26-week FIX primary endpoint and to feature these promising data at the upcoming ASH conference. Based on interactions with the FDA and EMA, we plan to incorporate FIX activity and bleeding rates at 52 weeks as additional co-primary endpoints in the study. We look forward to holding our pre-BLA meeting with the FDA and completing the last patient's 52-week follow-up visit in the first quarter of 2021."

    About Etranacogene Dezaparvovec

    Etranacogene dezaparvovec consists of an AAV5 viral vector carrying a gene cassette with the patent-protected Padua variant of Factor IX (FIX-Padua). uniQure holds multiple issued patents in the United States and Canada broadly covering methods of treating bleeding disorders, including hemophilia B, using AAV gene therapy with the FIX-Padua variant. Etranacogene dezaparvovec has been granted Breakthrough Therapy Designation by the United States Food and Drug Administration and access to Priority Medicine (PRIME) regulatory initiative by the European Medicines Agency.   In June 2020, the Company and CSL Behring entered into a licensing agreement providing CSL Behring with exclusive global rights to etranacogene dezaparvovec. This licensing agreement is subject to antitrust regulatory review in the United States, Australia and the United Kingdom that is currently ongoing.

    AAV5-based gene therapies have been demonstrated to be safe and well tolerated in a multitude of clinical trials, including five uniQure trials conducted in nearly 80 patients in hemophilia B and other indications. No patient treated in clinical trials with the uniQure's AAV5 gene therapies has experienced any confirmed cytotoxic T-cell-mediated immune response to the capsid. Additionally, pre-clinical and clinical data show that AAV5-based gene therapies may be viable treatments in patients with pre-existing antibodies to AAV5, thereby potentially increasing patient eligibility for treatment compared to other gene therapy product candidates.

    _______________________

    1 Total bleeds include any bleeding event reported after the treatment of etranacogene dezaparvovec, including spontaneous, traumatic, and those associated with unrelated medical procedures, whether or not FIX treatment was required.

    About uniQure

    uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com  

    uniQure Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, whether etranacogene dezaparvovec will be the first-in-class or best-in-class gene therapy for patients with hemophilia B, whether AAV5-based gene therapies can provide clinical benefit to patients with pre-existing neutralizing antibodies, and whether uniQure will conduct the 52-week follow-up visit of the last patient and its pre-BLA meeting with the FDA in the first quarter of 2021 or ever. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our and our collaborators' clinical development activities, clinical results, collaboration arrangements, corporate reorganizations and strategic shifts, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's Quarterly Report on Form 10-Q filed on October 27, 2020. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

    uniQure Contacts

    FOR INVESTORS:   FOR MEDIA:
         
    Maria E. Cantor Chiara Russo Tom Malone
    Direct: 339-970-7536 Direct: 617-306-9137 Direct: 339-970-7558
    Mobile: 617-680-9452 Mobile: 617-306-9137 Mobile:339-223-8541
      





    Primary Logo

    View Full Article Hide Full Article
  4. LEXINGTON, Mass. and AMSTERDAM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation and three poster presentations, will be delivered at the 62nd American Society of Hematology (ASH) Annual Meeting, which will be held December 5-8 as a virtual event.

    "We expect to have a strong presence at the virtual ASH annual meeting next month, and look forward to having long-term follow-up data presented from our hemophilia B gene therapy studies, including two years of follow-up on the Phase IIb clinical trial of etranacogene dezaparvovec (AMT-061) and up to…

    LEXINGTON, Mass. and AMSTERDAM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation and three poster presentations, will be delivered at the 62nd American Society of Hematology (ASH) Annual Meeting, which will be held December 5-8 as a virtual event.

    "We expect to have a strong presence at the virtual ASH annual meeting next month, and look forward to having long-term follow-up data presented from our hemophilia B gene therapy studies, including two years of follow-up on the Phase IIb clinical trial of etranacogene dezaparvovec (AMT-061) and up to five years of follow-up from the Phase I/II clinical trial of AMT-060," stated Matt Kapusta, chief executive officer at uniQure. "We also remain on track to announce top-line data from the pivotal HOPE-B study of etranacogene dezaparvovec before the end of this year, either at ASH or through a company presentation."

    Oral Presentation

    Title:Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B: Two Year Data from a Phase 2b Trial
    Presenter:Annette von Drygalski, M.D., PharmD
    Session Name:801. Gene Editing, Therapy and Transfer I
    Date:Monday, December 7, 2020
    Presentation Time:2:45 p.m. ET (11:45 a.m. PT)
      

    Poster Presentations

    Title:AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for up to 5 Years
    Session Name:801. Gene Editing, Therapy and Transfer: Poster III
    Date:Monday, December 7, 2020
    Presentation Time:10:00 a.m. - 6:30 p.m. ET (7:00 a.m. - 3:30 p.m. PT)
      
    Title:A Single Administration of AAV5-hFIX in Newborn, Juvenile and Adult Mice Leads to Stable hFIX Expression up to 18 Months after Dosing
    Session Name:801. Gene Editing, Therapy and Transfer: Poster II
    Date:Sunday, December 6, 2020
    Presentation Time:10:00 a.m. - 6:30 p.m. ET (7:00 a.m. - 3:30 p.m. PT)
      
    Title:Examining the Hemophilia Disability Paradox
    Session Name:904. Outcomes Research—Non-Malignant Conditions: Poster II
    Date:Sunday, December 6, 2020
    Presentation Time:10:00 a.m. - 6:30 p.m. ET (7:00 a.m. - 3:30 p.m. PT)

    The conference abstracts were made available today and can be accessed through this link: ASH abstracts.

    About uniQure

    uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

    uniQure Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, whether we will present long-term follow-up data from our hemophilia B gene therapy studies, including two years of follow-up on the Phase IIb clinical trial of etranacogene dezaparvovec (AMT-061) and up to five years of follow-up from the Phase I/II clinical trial of AMT-060, and whether we will announce top-line data from the pivotal HOPE-B study of etranacogene dezaparvovec before the end of this year. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our and our collaborators' clinical development activities, clinical results, collaboration arrangements, corporate reorganizations and strategic shifts, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's Quarterly Report on Form 10-Q filed on October 27, 2020. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

    uniQure Contacts:

    FOR INVESTORS: FOR MEDIA:
       
    Maria E. CantorChiara RussoTom Malone
    Direct: 339-970-7536Direct: 617-306-9137Direct: 339-970-7558
    Mobile: 617-680-9452Mobile: 617-306-9137Mobile:339-223-8541

    Primary Logo

    View Full Article Hide Full Article
  5. LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that members of uniQure's management team including Matt Kapusta, chief executive officer, Ricardo Dolmetsch, Ph.D., president of research & development, and Maria Cantor, chief communications officer, with Chiara Russo, associate director of investor relations and communications, will participate in the following upcoming conferences in November:

    • Credit Suisse 29th Annual Virtual Healthcare Conference, November 9 - 12, 2020

      — A fireside chat including Matt Kapusta and Dr. Dolmetsch with research analyst Martin…

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that members of uniQure's management team including Matt Kapusta, chief executive officer, Ricardo Dolmetsch, Ph.D., president of research & development, and Maria Cantor, chief communications officer, with Chiara Russo, associate director of investor relations and communications, will participate in the following upcoming conferences in November:

    • Credit Suisse 29th Annual Virtual Healthcare Conference, November 9 - 12, 2020



      — A fireside chat including Matt Kapusta and Dr. Dolmetsch with research analyst Martin Auster will take place on Monday, November 9, 2020 from 4:15 – 4:55 p.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.



      — Members of uniQure's management team also will participate in virtual one-on-one investor meetings throughout the day.
    • Barclay's Gene Editing & Gene Therapy Summit, November 16, 2020



      — A fireside chat with Matt Kapusta and research analyst Gena Wang will take place on Monday, November 16, 2020 from 2:30 – 2:55 p.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.



      — Members of uniQure's management team also will participate in virtual one-on-one investor meetings throughout the day.
    • Stifel 2020 Virtual Healthcare Conference, November 16 - 18, 2020



      — A fireside chat with Dr. Dolmetsch and research analyst Paul Matteis will take place on Tuesday, November 17, 2020 from 8:00 – 8:30 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investor section of the uniQure website. The webcast replay will be available for at least 72 hours following the live event.



      — Members of uniQure's management team will participate in virtual one-on-one investor meetings throughout the day.

    About uniQure

    uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

    uniQure Contacts:

    FOR INVESTORS: FOR MEDIA:
    Maria E. CantorChiara RussoTom Malone
    Direct: 339-970-7536Direct: 617-306-9137Direct: 339-970-7558

    Primary Logo

    View Full Article Hide Full Article
View All uniQure N.V. News